USD 9.2B of VC/PE investment in lifescience firms in Mar’21

We recorded 130 VC/PE transactions pertaining to the global life sciences sector for March 2021, aggregating to a sum of USD 9.2B. This is an all-time high deal count as well as amount. The USA recorded 86 transactions with total investment of USD 6.3B. China reported investment of USD 1.7B…

Read More

BeiGene bags blockbuster deal with Anti-PD-1 Antibody Tislelizumab

BeiGene’s outlicensing deal with Novartis underscores how Chinese pharma companies are yards ahead of Indian pharma companies now. Novartis, the Swiss Big Pharma company, has agreed to pay BeiGene  $650 million upfront and up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales. This is in exchange…

Read More

EQRx and Equivalars: A new biotech with a potentially radical business model

Founded in 2019, EQRx has closed 2 massive rounds in under 13 months. It first raised a Series-A round of USD200m in Jan’20 as part of its launch. Then in Jan’21, it has again shaken up the pharma world with a USD500m Series-B EQRx is targeting Equivalar medicines EQRx’ stated…

Read More

USD 6.3B of VC/PE investment in lifescience firms in Jan’21

We recorded 114 venture capital / private equity (VC/PE) transactions pertaining to the global life sciences sector for January 2021, aggregating to a sum of USD 6.275B. USA recorded 64 transactions for with total investment of USD 4B. China reported investment of USD 1B over 15 VC/PE transactions. India saw…

Read More

USD 4.5B of VC / PE investment seen in Lifesciences spaces in December 2020

We recorded 78 VC/PE transactions pertaining to the global life sciences sector for Dec 2020, aggregating to a sum of USD 4.5B. USA recorded 46 transactions for with total investment of USD 2.1B. China reported investment of USD 1.9B over 14 VC/PE transactions. China also reported 3 IPOs  aggregating a…

Read More

USD 4.7B of VC/PE investment seen in Lifesciences spaces in November 2020

We recorded 81 VC/PE transactions pertaining to the global life sciences sector for Nov 2020, aggregating to a sum of USD 4.7B. USA recorded 46 transactions for with total investment of USD 2.5B. Around 67% of investment, spread over 40 transactions, went into supporting R&D stage companies. Vaccine companies continued…

Read More

USD 5.6B of investments into Lifesciences startups in September’20

We recorded 96 VC/PE transactions pertaining to the global life sciences sector for Sep 2020, aggregating to a sum of USD 5.6B. USA recorded 52 transactions for with total investment of USD 2.6B. China reported investment of USD 1.5B over 16 VC/PE transactions. China also reported 2 IPOs aggregating to…

Read More

China’s lifescience sector receives more VC/PE investment in Aug’20 compared to the USA

Aug’20 saw China’s lifescience sector receive more VC/PE investment than the USA for the second time ever in terms of monthly recorded amounts, with the first instance being in Apr’20. For Aug’20, China reported USD 2024m of venture capital investments, as compared to USD 1531m recorded by the USA. China…

Read More

July was a landmark month for Chinese Biotech

China’s biotech sector continues to blossom as far as fund raising goes. For 4 months in a row, the sector is witnessing increasing amounts of fund raise. While private deals (VC/PE) led the increase in April and May, in June and July, it is public market fund raising that drove…

Read More

China’s Booming Biotech IPOs

We have earlier commented on the sharply accelerated venture capital activity in the biotech sector in China. From around 2-3 deals a month, aggregating maybe USD100m 2-3 years ago, China is now witnessing close to USD1B of venture capital investments in biotech sector on a  monthly basis. Keeping company is…

Read More